Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 13/20 | 0.38 |
| ▸ | MME | P08473 | 10/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8058387 | 1.00 | AGTR1 (0.38) | AGTR1MMEAGTR2ITGB3ITGA2B | |
| SCHEMBL489591 | 1.00 | AGTR1 (0.38) | AGTR1MMEAGTR2ITGB3ITGA2B | |
| SCHEMBL489485 | 0.94 | AGTR1 (0.38) | AGTR1MMEAGTR2ITGB3ITGA2B | |
| SCHEMBL489411 | 0.94 | AGTR1 (0.39) | AGTR1MMEAGTR2LTB4R2 | |
| SCHEMBL489778 | 0.93 | CCKBR (0.40) | AGTR1MMEAGTR2 | |
| SCHEMBL489776 | 0.93 | CCKBR (0.40) | AGTR1MMEAGTR2 | |
| SCHEMBL3695208 | 0.92 | AGTR1 (0.39) | AGTR1AGTR2ITGB3ITGA2BLTB4R2 | |
| SCHEMBL1282992 | 0.92 | AGTR1 (0.39) | AGTR1AGTR2ITGB3ITGA2BLTB4R2 | |
| SCHEMBL1282994 | 0.92 | AGTR1 (0.39) | AGTR1AGTR2ITGB3ITGA2BLTB4R2 | |
| SCHEMBL489189 | 0.91 | AGTR1 (0.38) | AGTR1MMEAGTR2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106082-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7834041-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834041-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | AGTR1 1/4885MME 5/4885AGTR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.